Trade Mark Journal No.2026/036 4 September 2026

WO0000001932846 (5)

Office of origin: United States of America

Date of International Registration:16 June 2026
Date of designation in the UK: 16 June 2026
Image for mark 1932846 NEREUS

Class 5
Pharmaceutical preparations for the treatment of gastroparesis; pharmaceutical preparations for the treatment and prevention of motion sickness; pharmaceutical preparations for the treatment and prevention of nausea; pharmaceutical preparations for the treatment and prevention of vomiting; pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance p; pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; pharmaceutical preparations for the treatment of nausea in gastroparesis; pharmaceutical preparations for the treatment of symptoms of gastroparesis; pharmaceutical preparations for the treatment and prevention of vomiting induced by motion; pharmaceutical preparations for the treatment of vomiting in gastroparesis; pharmaceutical preparations for the treatment and prevention of nausea induced by motion.

Vanda Pharmaceuticals Inc.

Representative: Jayme M. Torelli Hoffman Warnick LLC, 6 Tower Place, 1st Floor, Albany NY 12203, UNITED STATES OF AMERICA